코로나19 범유행을 대비하기 위한 이종교차접종의 선택
Heterologous Vaccination for Preparing COVID-19 Pandemic
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Infectious disease pandemics are characterized by extreme uncertainty. From the more predictable response to seasonal influenza, which occurs each year, we have learned the importance of effective universal vaccines and therapeutic agents to protect high-risk groups. Heterologous vaccination with different types of vaccines to prevent COVID-19 is already recommended for various reasons: shortages of mass vaccine supply; critical adverse events, and potential superior efficacy as a booster dose. However, very few studies have examined the efficacy and safety of heterologous vaccination with mixed types. This review discusses the efficacy of vaccines currently approved in the Republic of Korea, including heterologous vaccination options.
Abstract
Infectious disease pandemics are characterized by extreme uncertainty. From the more predictable response to seasonal influenza, which occurs each year, we have learned the importance of effective universal vaccines and therapeutic agents to protect high-risk groups. Heterologous vaccination with different types of vaccines to prevent COVID-19 is already recommended for various reasons: shortages of mass vaccine supply; critical adverse events, and potential superior efficacy as a booster dose. However, very few studies have examined the efficacy and safety of heterologous vaccination with mixed types. This review discusses the efficacy of vaccines currently approved in the Republic of Korea, including heterologous vaccination options.
참고문헌 (16)
- Monto AS, "Lessons from influenza pandemics of the last 100 years", Clin Infect Dis, 70, pp.951~957 (2020)
- Hayden FG, "Baloxavir marboxil for uncomplicated influenza in adults and adolescents", N Engl J Med, 379, pp.913~923 (2018)
- Boulware DR, "A randomized trial of hydroxychloroquine as postexposure prophylaxis for COVID-19", N Engl J Med, 383, pp.517~525 (2020)
- Krammer F, "SARS-CoV-2 vaccines in development", Nature, 586, pp.516~527 (2020)
- Voysey M, "Safety and efficacy of the ChAdOx1 nCoV-19 vaccine(AZD1222)against SARS-CoV-2 : an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK", Lancet, 397, pp.99~111 (2021)
- Lopez Bernal J, "Effectiveness of COVID-19 vaccines against the B.1.617.2 (Delta) Variant", N Engl J Med, 385, pp.585~594 (2021)
- Ann R. Falsey, "Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine", New England Journal of Medicine, 385(25), pp.2348~2360 (2021), Massachusetts Medical Society[DOI]
- Sadoff J, "Safety and efficacy of single-dose Ad26.COV2.S vaccine against COVID-19", N Engl J Med, 384, pp.2187~2201 (2021)
- Polack FP, "Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine", N Engl J Med, 383, pp.2603~2615 (2020)
- Frenck RW Jr, "Safety, immunogenicity, and efficacy of the BNT162b2 COVID-19vaccine in adolescents", N Engl J Med, 385, pp.239~250 (2021)
- Baden LR, "Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine", N Engl J Med, 384, pp.403~416 (2021)
- Borobia AM, "Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants(CombiVacS) : a multicentre, open-label, randomised, controlled, phase 2 trial", Lancet, 398, pp.121~130 (2021)
- Normark J, "Heterologous ChAdOx1 nCoV-19 and mRNA-1273 vaccination", N Engl J Med, 385, pp.1049~1051 (2021)
- Jackson LA, "Effect of varying doses of a monovalent H7N9 influenza vaccine with and without AS03 and MF59 adjuvants on immune response : a randomized clinical trial", JAMA, 314, pp.237~246 (2015)
- Fauci AS, "Pandemic influenza threat and preparedness", Emerg Infect Dis, 12, pp.73~77 (2006)
- Zelner J, "Racial disparities in coronavirus disease 2019 (COVID-19) mortality are driven by unequal infection risks", Clin Infect Dis., 72, pp.e88~e95 (2021)